Treatment of Metastatic Colorectal Cancer : ASCO Guideline
PURPOSE: To develop recommendations for treatment of patients with metastatic colorectal cancer (mCRC).
METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice.
RESULTS: Five systematic reviews and 10 randomized controlled trials met the systematic review inclusion criteria.
RECOMMENDATIONS: Doublet chemotherapy should be offered, or triplet therapy may be offered to patients with previously untreated, initially unresectable mCRC, on the basis of included studies of chemotherapy in combination with anti-vascular endothelial growth factor antibodies. In the first-line setting, pembrolizumab is recommended for patients with mCRC and microsatellite instability-high or deficient mismatch repair tumors; chemotherapy and anti-epidermal growth factor receptor therapy is recommended for microsatellite stable or proficient mismatch repair left-sided treatment-naive RAS wild-type mCRC; chemotherapy and anti-vascular endothelial growth factor therapy is recommended for microsatellite stable or proficient mismatch repair RAS wild-type right-sided mCRC. Encorafenib plus cetuximab is recommended for patients with previously treated BRAF V600E-mutant mCRC that has progressed after at least one previous line of therapy. Cytoreductive surgery plus systemic chemotherapy may be recommended for selected patients with colorectal peritoneal metastases; however, the addition of hyperthermic intraperitoneal chemotherapy is not recommended. Stereotactic body radiation therapy may be recommended following systemic therapy for patients with oligometastases of the liver who are not considered candidates for resection. Selective internal radiation therapy is not routinely recommended for patients with unilobar or bilobar metastases of the liver. Perioperative chemotherapy or surgery alone should be offered to patients with mCRC who are candidates for potentially curative resection of liver metastases. Multidisciplinary team management and shared decision making are recommended. Qualifying statements with further details related to implementation of guideline recommendations are also included.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 41(2023), 3 vom: 20. Jan., Seite 678-700 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Morris, Van K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cetuximab |
|---|
| Anmerkungen: |
Date Completed 26.01.2023 Date Revised 19.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1200/JCO.22.01690 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347670571 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347670571 | ||
| 003 | DE-627 | ||
| 005 | 20231226034402.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.22.01690 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1158.xml |
| 035 | |a (DE-627)NLM347670571 | ||
| 035 | |a (NLM)36252154 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Morris, Van K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment of Metastatic Colorectal Cancer |b ASCO Guideline |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.01.2023 | ||
| 500 | |a Date Revised 19.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: To develop recommendations for treatment of patients with metastatic colorectal cancer (mCRC) | ||
| 520 | |a METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice | ||
| 520 | |a RESULTS: Five systematic reviews and 10 randomized controlled trials met the systematic review inclusion criteria | ||
| 520 | |a RECOMMENDATIONS: Doublet chemotherapy should be offered, or triplet therapy may be offered to patients with previously untreated, initially unresectable mCRC, on the basis of included studies of chemotherapy in combination with anti-vascular endothelial growth factor antibodies. In the first-line setting, pembrolizumab is recommended for patients with mCRC and microsatellite instability-high or deficient mismatch repair tumors; chemotherapy and anti-epidermal growth factor receptor therapy is recommended for microsatellite stable or proficient mismatch repair left-sided treatment-naive RAS wild-type mCRC; chemotherapy and anti-vascular endothelial growth factor therapy is recommended for microsatellite stable or proficient mismatch repair RAS wild-type right-sided mCRC. Encorafenib plus cetuximab is recommended for patients with previously treated BRAF V600E-mutant mCRC that has progressed after at least one previous line of therapy. Cytoreductive surgery plus systemic chemotherapy may be recommended for selected patients with colorectal peritoneal metastases; however, the addition of hyperthermic intraperitoneal chemotherapy is not recommended. Stereotactic body radiation therapy may be recommended following systemic therapy for patients with oligometastases of the liver who are not considered candidates for resection. Selective internal radiation therapy is not routinely recommended for patients with unilobar or bilobar metastases of the liver. Perioperative chemotherapy or surgery alone should be offered to patients with mCRC who are candidates for potentially curative resection of liver metastases. Multidisciplinary team management and shared decision making are recommended. Qualifying statements with further details related to implementation of guideline recommendations are also included.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Cetuximab |2 NLM | |
| 650 | 7 | |a PQX0D8J21J |2 NLM | |
| 650 | 7 | |a Endothelial Growth Factors |2 NLM | |
| 700 | 1 | |a Kennedy, Erin B |e verfasserin |4 aut | |
| 700 | 1 | |a Baxter, Nancy N |e verfasserin |4 aut | |
| 700 | 1 | |a Benson, Al B |c 3rd |e verfasserin |4 aut | |
| 700 | 1 | |a Cercek, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, May |e verfasserin |4 aut | |
| 700 | 1 | |a Ciombor, Kristen K |e verfasserin |4 aut | |
| 700 | 1 | |a Cremolini, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Anjee |e verfasserin |4 aut | |
| 700 | 1 | |a Deming, Dustin A |e verfasserin |4 aut | |
| 700 | 1 | |a Fakih, Marwan G |e verfasserin |4 aut | |
| 700 | 1 | |a Gholami, Sepideh |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Theodore S |e verfasserin |4 aut | |
| 700 | 1 | |a Jaiyesimi, Ishmael |e verfasserin |4 aut | |
| 700 | 1 | |a Klute, Kelsey |e verfasserin |4 aut | |
| 700 | 1 | |a Lieu, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Sanoff, Hanna |e verfasserin |4 aut | |
| 700 | 1 | |a Strickler, John H |e verfasserin |4 aut | |
| 700 | 1 | |a White, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Willis, Jason A |e verfasserin |4 aut | |
| 700 | 1 | |a Eng, Cathy |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology : official journal of the American Society of Clinical Oncology |d 1986 |g 41(2023), 3 vom: 20. Jan., Seite 678-700 |w (DE-627)NLM012608777 |x 1527-7755 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2023 |g number:3 |g day:20 |g month:01 |g pages:678-700 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.22.01690 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2023 |e 3 |b 20 |c 01 |h 678-700 | ||